Research Grants show all

NIH1

Patents show all

AxoGen has 1 licensable patents.
26Issued20Applications

Clinical Trials show all

2Phase 41N/A1Phase 3

SEC Filings show all

8-K9510-Q5510-K17D1S-11

SEC Form D Funding Events

DateOfferedSoldType
2011-10-13$1,000,000$1,000,000Equity

Key Executives

  • Karen Zaderej
    Executive Officer, Director
  • Gregory G. Freitag
    Executive Officer, Director
  • John P. Engels
    Executive Officer
  • Brad Hedger
    Executive Officer
  • Mark Friedman
    Executive Officer
  • David Hansen
    Executive Officer
  • Jamie M. Grooms
    Director
  • Mark Gold
    Director
  • John Harper
    Director
  • Joe Mandato
    Director
  • Robert J. Rudelius
    Director